Anti-Human Fibulin-4 – Purified in vivo GOLD™ Functional Grade

Recombinant, human Fibulin-4 produced in E. coli BL21 cells.

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone 5G11 recognizes Human Fibulin-4. Monoclonal antibodies raised against the purified proteins did not show any crossreactivity with other family members.

Fibulin-4 is predominantly expressed in tissues rich in elastic fibers.

There are currently seven genes in the fibulin family (Fibulin-1, 2, 3, 4, 5, 6, and 7) that are associated with elastic fibers. The fibulins are widely distributed throughout the body and are more prominent in tissues rich in elastic fibers and are often associated with vasculature and elastic tissues. Fibulin-4 appears to be the most critical member of this family of proteins in modulating elastic-fiber formation because studies have shown that fibulin-4-null mice do not produce elastic fibers at all.¹ This extracellular glycoprotein has a molecular weight of approximately 49 kD, and is not only considered a structural protein of the extracellular matrix, but also a regulatory factor required for normal elastin expression in human fibroblasts.² Due to the regulatory role of Fibulin-4, it is thought that a pathophysiological link may exist between the modulation of fibulin-4 levels and diseases, such as WBS (Williams-Beuren syndrome), that are characterized by impaired elastic-fiber formation.¹ Furthermore, fibulin-4 has been shown to interact with P53, a crucial homologous protein that prevents cancer formation, and thus functions as a tumor suppressor.³ One study indicated that colon tumors were found to have approximately 2-7-fold increases of fibulin-4 mRNA expression. This suggests that the dysregulated expression of the fibulin-4 gene is associated with human colon tumourigenesis.⁴

1. DiCorleto, PE. et al. (2009) Biochem J. 423(1): 79–89.
2. Kobayashi, N. et al. (2007) J Biol Chem. 282(16):11805-16.
3. Gallagher, WM. et al. (1999) Oncogene. 18(24):3608-16.
4. Gallagher, WM. et al. (2001) FEBS Lett. 489(1):59-66.